CCL2 was recently found to be a diagnostic, predictive, and prognostic biomarker of prostate cancer [29] and has been reported to be the most important chemokine for monocyte recruitment to prostate tumors [17, 30]. Here, CCL2 is linked to prostate neoplasm.